EVE and Ferring sign sponsorship agreement to support Femtech in Israel
Tel Aviv, Israel, February 1st
EVE has signed a sponsorship agreement with Ferring Pharmaceuticals, where Ferring will support an accelerator focusing on Femtech-related innovations that will be managed by EVE, a Femtech Hub recently co-founded in Israel,
by Dr. Sharon Rashi-Elkeles and Mr. Tal Catran. “I am delighted and excited to sign this important agreement with Ferring”, said Dr. Sharon Rashi-Elkles, CEO & co-Founder of EVE. “This will enable EVE to immediately activate its accelerator in the field of women’s health. The support and the tailwind from a company like Ferring, which is a leader in reproductive medicine and women’s health, is critical to our success.“We are thrilled to contribute to the advancement of promising Femtech innovation through this agreement. This should help us develop solutions to unmet needs in women’s health and ultimately provide an opportunity to build more families worldwide’’ said Catherine Aung, Head of Global Innovation Lab, Ferring Pharmaceuticals.
EVE is an innovations hub aimed at promoting the Femtech sector in Israel, while helping
Femtechers (entrepreneurs with technological ideas relating to women healthcare) to
ideate and accelerate their innovations.
EVE is much more than an accelerator designed for speeding up companies’ development
with a few months of mentorship, networking and MVP launch; It is the infrastructure for a
wide and prosperous Femtech ecosystem, that will encompass aspiring entrepreneurs
with ideas regrading women healthcare, entrepreneurs already leading a startup in the
field, professional experts and mentors, investors, companies that are selling women
health-related products and any player related to women healthcare industry.
For more information, please contact:
Dr. Sharon Rashi-Elkeles
CEO & co-Founder
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group
committed to helping people around the world build families and live better lives.
Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine
and women’s health, and in specialty areas within gastroenterology and urology. Ferring
has been developing treatments for mothers and babies for over 50 years and has a
portfolio covering treatments from conception to birth. Founded in 1950, privately-owned
Ferring now employs approximately 6,500 people worldwide, has its own operating
subsidiaries in nearly 60 countries and markets its products in 110 countries.
Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram,